0 XP   0   0   0

Cardiff Oncology Inc










Financial Health of Cardiff Oncology Inc




Comparing to competitors in the Biotechnology industry




  Industry Rankings  


Cardiff Oncology Inc
Buy, Hold or Sell?

Should you buy, hold or sell Cardiff Oncology Inc?

I guess you are interested in Cardiff Oncology Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Cardiff Oncology Inc

Let's start. I'm going to help you getting a better view of Cardiff Oncology Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Cardiff Oncology Inc even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Cardiff Oncology Inc is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Cardiff Oncology Inc. The closing price on 2022-12-06 was $1.49 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Cardiff Oncology Inc Daily Candlestick Chart

Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Cardiff Oncology Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Cardiff Oncology Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Cardiff Oncology Inc to the Biotechnology industry mean.
  • A Net Profit Margin of -9,222.6% means that $-92.23 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Cardiff Oncology Inc:

  • The MRQ is -9,222.6%. The company is making a huge loss. -2
  • The TTM is -10,663.3%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-9,222.6%TTM-10,663.3%+1,440.7%
TTM-10,663.3%YOY-7,675.0%-2,988.2%
TTM-10,663.3%5Y-6,473.4%-4,189.8%
5Y-6,473.4%10Y-7,184.0%+710.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9,222.6%-223.6%-8,999.0%
TTM-10,663.3%-281.7%-10,381.6%
YOY-7,675.0%-344.8%-7,330.2%
5Y-6,473.4%-450.1%-6,023.3%
10Y-7,184.0%-541.0%-6,643.0%
1.1.2. Return on Assets

Shows how efficient Cardiff Oncology Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Cardiff Oncology Inc to the Biotechnology industry mean.
  • -6.9% Return on Assets means that Cardiff Oncology Inc generated $-0.07 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Cardiff Oncology Inc:

  • The MRQ is -6.9%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -7.3%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-6.9%TTM-7.3%+0.3%
TTM-7.3%YOY-4.6%-2.7%
TTM-7.3%5Y-18.3%+11.0%
5Y-18.3%10Y-21.3%+3.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-6.9%-9.9%+3.0%
TTM-7.3%-8.9%+1.6%
YOY-4.6%-9.3%+4.7%
5Y-18.3%-11.7%-6.6%
10Y-21.3%-12.7%-8.6%
1.1.3. Return on Equity

Shows how efficient Cardiff Oncology Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Cardiff Oncology Inc to the Biotechnology industry mean.
  • -7.6% Return on Equity means Cardiff Oncology Inc generated $-0.08 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Cardiff Oncology Inc:

  • The MRQ is -7.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -7.9%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-7.6%TTM-7.9%+0.3%
TTM-7.9%YOY-4.8%-3.0%
TTM-7.9%5Y-29.3%+21.5%
5Y-29.3%10Y-45.8%+16.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-7.6%-12.0%+4.4%
TTM-7.9%-11.5%+3.6%
YOY-4.8%-10.8%+6.0%
5Y-29.3%-14.2%-15.1%
10Y-45.8%-15.2%-30.6%

1.2. Operating Efficiency of Cardiff Oncology Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Cardiff Oncology Inc is operating .

  • Measures how much profit Cardiff Oncology Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Cardiff Oncology Inc to the Biotechnology industry mean.
  • An Operating Margin of -9,669.9% means the company generated $-96.70  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Cardiff Oncology Inc:

  • The MRQ is -9,669.9%. The company is operating very inefficient. -2
  • The TTM is -10,646.8%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-9,669.9%TTM-10,646.8%+976.9%
TTM-10,646.8%YOY-7,654.7%-2,992.1%
TTM-10,646.8%5Y-6,465.8%-4,181.0%
5Y-6,465.8%10Y-7,012.2%+546.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-9,669.9%-207.3%-9,462.6%
TTM-10,646.8%-271.0%-10,375.8%
YOY-7,654.7%-325.9%-7,328.8%
5Y-6,465.8%-454.0%-6,011.8%
10Y-7,012.2%-537.1%-6,475.1%
1.2.2. Operating Ratio

Measures how efficient Cardiff Oncology Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 97.70 means that the operating costs are $97.70 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Cardiff Oncology Inc:

  • The MRQ is 97.699. The company is inefficient in keeping operating costs low. -1
  • The TTM is 109.182. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ97.699TTM109.182-11.484
TTM109.182YOY79.186+29.997
TTM109.1825Y66.525+42.657
5Y66.52510Y69.536-3.011
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ97.6992.871+94.828
TTM109.1823.504+105.678
YOY79.1863.604+75.582
5Y66.5255.132+61.393
10Y69.5366.371+63.165

1.3. Liquidity of Cardiff Oncology Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Cardiff Oncology Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 14.52 means the company has $14.52 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Cardiff Oncology Inc:

  • The MRQ is 14.525. The company is very able to pay all its short-term debts. +2
  • The TTM is 18.051. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ14.525TTM18.051-3.527
TTM18.051YOY27.256-9.205
TTM18.0515Y11.437+6.614
5Y11.43710Y10.224+1.213
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ14.5255.117+9.408
TTM18.0515.755+12.296
YOY27.2565.854+21.402
5Y11.4376.511+4.926
10Y10.2246.222+4.002
1.3.2. Quick Ratio

Measures if Cardiff Oncology Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Cardiff Oncology Inc to the Biotechnology industry mean.
  • A Quick Ratio of 25.54 means the company can pay off $25.54 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Cardiff Oncology Inc:

  • The MRQ is 25.535. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 32.246. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ25.535TTM32.246-6.710
TTM32.246YOY45.971-13.725
TTM32.2465Y17.861+14.384
5Y17.86110Y13.299+4.562
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ25.5354.284+21.251
TTM32.2464.664+27.582
YOY45.9714.787+41.184
5Y17.8615.218+12.643
10Y13.2995.182+8.117

1.4. Solvency of Cardiff Oncology Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Cardiff Oncology Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Cardiff Oncology Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.08 means that Cardiff Oncology Inc assets are financed with 8.4% credit (debt) and the remaining percentage (100% - 8.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Cardiff Oncology Inc:

  • The MRQ is 0.084. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.073. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.084TTM0.073+0.011
TTM0.073YOY0.043+0.030
TTM0.0735Y0.230-0.156
5Y0.23010Y0.393-0.164
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0840.278-0.194
TTM0.0730.277-0.204
YOY0.0430.306-0.263
5Y0.2300.367-0.137
10Y0.3930.403-0.010
1.4.2. Debt to Equity Ratio

Measures if Cardiff Oncology Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Cardiff Oncology Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 9.2% means that company has $0.09 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Cardiff Oncology Inc:

  • The MRQ is 0.092. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.079. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.092TTM0.079+0.013
TTM0.079YOY0.046+0.034
TTM0.0795Y0.376-0.297
5Y0.37610Y0.843-0.467
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.0920.315-0.223
TTM0.0790.317-0.238
YOY0.0460.319-0.273
5Y0.3760.403-0.027
10Y0.8430.462+0.381

2. Market Valuation of Cardiff Oncology Inc

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Cardiff Oncology Inc generates.

  • Above 15 is considered overpriced but always compare Cardiff Oncology Inc to the Biotechnology industry mean.
  • A PE ratio of -7.78 means the investor is paying $-7.78 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Cardiff Oncology Inc:

  • The EOD is -7.528. Company is losing money. -2
  • The MRQ is -7.781. Company is losing money. -2
  • The TTM is -13.560. Company is losing money. -2
Trends
Current periodCompared to+/- 
EOD-7.528MRQ-7.781+0.253
MRQ-7.781TTM-13.560+5.780
TTM-13.560YOY-69.945+56.385
TTM-13.5605Y-31.622+18.062
5Y-31.62210Y-42.031+10.408
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.528-8.986+1.458
MRQ-7.781-9.792+2.011
TTM-13.560-16.243+2.683
YOY-69.945-20.876-49.069
5Y-31.622-16.665-14.957
10Y-42.031-14.732-27.299
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Cardiff Oncology Inc.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Cardiff Oncology Inc:

  • The MRQ is -35.649. Very Bad. -2
  • The TTM is -9.179. Very Bad. -2
Trends
Current periodCompared to+/- 
MRQ-35.649TTM-9.179-26.471
TTM-9.179YOY530.216-539.395
TTM-9.1795Y758.365-767.544
5Y758.36510Y-1.084+759.449
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-35.649-0.032-35.617
TTM-9.1790.004-9.183
YOY530.2160.016+530.200
5Y758.3650.006+758.359
10Y-1.0840.003-1.087

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Cardiff Oncology Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.59 means the investor is paying $0.59 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Cardiff Oncology Inc:

  • The EOD is 0.570. Very good. +2
  • The MRQ is 0.589. Very good. +2
  • The TTM is 1.015. Good. +1
Trends
Current periodCompared to+/- 
EOD0.570MRQ0.589-0.019
MRQ0.589TTM1.015-0.426
TTM1.015YOY3.383-2.368
TTM1.0155Y5.507-4.492
5Y5.50710Y10.906-5.399
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD0.5701.835-1.265
MRQ0.5892.006-1.417
TTM1.0152.774-1.759
YOY3.3833.453-0.070
5Y5.5072.713+2.794
10Y10.9062.402+8.504
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Cardiff Oncology Inc.

3.1. Institutions holding Cardiff Oncology Inc

Institutions are holding 20.747% of the shares of Cardiff Oncology Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-06-30Vanguard Group Inc4.05140.00011755656-157757-8.2448
2022-06-30Artal Group S A1.73070.088175000000
2022-06-30Renaissance Technologies Corp1.67910.001972761623615848.0525
2022-06-30LAURION CAPITAL MANAGEMENT LP1.66630.02457221007221000
2022-06-30Geode Capital Management, LLC0.9510.0001412110-257719-38.4753
2022-06-30Millennium Management LLC0.90830.000539360310860938.1092
2022-06-30Two Sigma Advisers, LLC0.77260.0021334800-179300-34.8765
2022-06-30Susquehanna International Group, LLP0.73610.0002318997217841215.3515
2022-06-30Chartwell Investment Partners, LLC0.68420.0261296507215514266.0897
2022-06-30Deutsche Bank AG0.5170.0003224057-20681-8.4503
2022-06-30Ergoteles LLC0.42460.01211840001840000
2022-09-30Assenagon Asset Management SA0.38430.001166534113447.3097
2022-06-30Mercer Global Advisors Inc.0.34120.00214785700
2022-06-30State Street Corporation0.32290139945-564292-80.1281
2022-06-30Blair William & Co0.30590.00131325754270047.5104
2022-06-30Citadel Advisors Llc0.29880.0001129497-472980-78.5059
2022-09-30ACT Capital Management, LLC0.27830.256712060000
2022-06-30GSA Capital Partners LLP0.27070.03871172955354683.995
2022-06-30Bank of America Corp0.230409983583370506.3468
2022-06-30Northern Trust Corp0.1537066592-251266-79.0498
Total 16.70750.45587240176-28813-0.4%

3.2. Funds holding Cardiff Oncology Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2022-09-30Vanguard Instl Ttl Stck Mkt Idx Tr2.96720.0002128584614791112.9982
2022-10-31Vanguard Total Stock Mkt Idx Inv2.96720.0002128584600
2022-10-31Vanguard Extended Market Index Investor1.36110.001258983700
2022-09-30DWS Biotech LC0.5170.086224061-3-0.0013
2022-09-30Fidelity® Extended Market Index0.48530.001221030100
2022-09-30BlackRock Extended Equity Market K0.2950.001912783970776124.0313
2022-10-31iShares Micro-Cap ETF0.18480.01438010200
2022-09-30Fidelity® Total Market Index0.17370.00027526000
2022-06-30BlackRock Extended Mkt Composite0.14780.001264039640390
2022-03-31iShares Russell 2000 Small-Cap Idx Instl0.12310.00315334600
2022-09-30Fidelity® Series Total Market Index0.11180.00024844000
2022-10-31iShares Core S&P Total US Stock Mkt ETF0.08860.00023838200
2022-09-30T. Rowe Price U.S. Equities Tr0.08420.00083650000
2022-09-30NT Ext Equity Mkt Idx Fd - NL0.07470.0013239100
2022-09-30NT Ext Equity Mkt Idx Fd - L0.07290.00123157227929.7012
2022-09-30Northern Trust Extended Eq Market Idx0.07290.00123157227929.7012
2022-10-31Vanguard Instl Ttl Stk Mkt Idx InstlPls0.0640.00022772700
2022-09-30Spartan Total Market Index Pool E0.06360.00022754200
2022-09-30NT Ext Equity Mkt Idx Fd - DC - NL - T20.06030.001261193491.3543
2022-10-31Dimensional US Targeted Value ETF0.05990.00062595700
Total 9.97510.11614322679+288656+6.7%

3.3. Insider Transactions

Insiders are holding 7.33% of the shares of Cardiff Oncology Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2022-09-19Lale WhiteBUY150001.64113788
2022-09-16James E LevineBUY300001.5660000
2022-09-15Renee P TannenbaumBUY100001.7210000
2021-09-21Gary W PaceBUY300006.75
2021-09-10James E LevineBUY300006.475000
2021-03-26Rodney S MarkinBUY290010.327181
2021-03-23Mark ErlanderBUY96510.3414481
2021-03-23Vicki KelemenBUY96010.316053
2021-03-22John P BrancaccioBUY300010.9512260
2021-03-18Gary W PaceBUY300010.55452811
2021-03-04Gary W PaceBUY15009.27451811
2020-09-16Gary W PaceBUY25505.7449461

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Cardiff Oncology Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.168-0.117-30%0.577-129%0.126-233%0.062-368%
Book Value Growth---0.064-0.044-32%0.193-133%0.058-211%-0.123+91%
Book Value Per Share--2.6122.909-10%3.031-14%1.360+92%0.901+190%
Book Value Per Share Growth---0.064-0.044-32%0.193-133%0.058-211%-0.123+91%
Current Ratio--14.52518.051-20%27.256-47%11.437+27%10.224+42%
Debt To Asset Ratio--0.0840.073+15%0.043+94%0.230-63%0.393-79%
Debt To Equity Ratio--0.0920.079+16%0.046+102%0.376-76%0.843-89%
Dividend Per Share--0.0000.000+20%-+100%0.000+360%0.000+821%
Dividend Per Share Growth--0.333-0.292+188%---0.033+110%-0.033+110%
Eps---0.198-0.228+15%-0.147-26%-0.138-30%-0.142-28%
Eps Growth--0.218-0.034+116%-0.075+134%0.018+1133%0.153+43%
Gross Profit Margin--1.0001.0000%1.0000%1.006-1%1.099-9%
Net Profit Margin---92.226-106.633+16%-76.750-17%-64.734-30%-71.840-22%
Operating Margin---96.699-106.468+10%-76.547-21%-64.658-33%-70.122-27%
Operating Ratio--97.699109.182-11%79.186+23%66.525+47%69.536+41%
Pb Ratio0.570-3%0.5891.015-42%3.383-83%5.507-89%10.906-95%
Pe Ratio-7.528+3%-7.781-13.560+74%-69.945+799%-31.622+306%-42.031+440%
Peg Ratio---35.649-9.179-74%530.216-107%758.365-105%-1.084-97%
Price Per Share1.490-3%1.5403.058-50%10.140-85%4.238-64%4.573-66%
Price To Total Gains Ratio-8.913+3%-9.2132.052-549%-36.286+294%-29.860+224%-45.063+389%
Profit Growth--21.756-3.468+116%-7.517+135%-0.622+103%14.065+55%
Quick Ratio--25.53532.246-21%45.971-44%17.861+43%13.299+92%
Return On Assets---0.069-0.073+5%-0.046-33%-0.183+163%-0.213+206%
Return On Equity---0.076-0.079+4%-0.048-36%-0.293+287%-0.458+504%
Revenue Growth--0.022-0.059+374%-0.162+855%-0.142+762%-0.157+832%
Total Gains Per Share---0.167-0.117-30%0.577-129%0.126-232%0.062-368%
Total Gains Per Share Growth--0.3270.127+157%-7.703+2452%-1.249+482%-1.159+454%
Usd Book Value--113212000.000126051250.000-10%131359220.500-14%58945996.750+92%39043868.275+190%
Usd Book Value Change Per Share---0.168-0.117-30%0.577-129%0.126-233%0.062-368%
Usd Book Value Per Share--2.6122.909-10%3.031-14%1.360+92%0.901+190%
Usd Dividend Per Share--0.0000.000+20%-+100%0.000+360%0.000+821%
Usd Eps---0.198-0.228+15%-0.147-26%-0.138-30%-0.142-28%
Usd Price Per Share1.490-3%1.5403.058-50%10.140-85%4.238-64%4.573-66%
Usd Profit---8577000.000-9863750.000+15%-6361511.750-26%-5652771.950-34%-5993666.575-30%
Usd Revenue--93000.00097750.000-5%86313.750+8%99542.550-7%93797.900-1%
Usd Total Gains Per Share---0.167-0.117-30%0.577-129%0.126-232%0.062-368%
 EOD+3 -2MRQTTM+18 -17YOY+11 -235Y+20 -1610Y+22 -14

4.2. Fundamental Score

Let's check the fundamental score of Cardiff Oncology Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.528
Price to Book Ratio (EOD)Between0-10.570
Net Profit Margin (MRQ)Greater than0-92.226
Operating Margin (MRQ)Greater than0-96.699
Quick Ratio (MRQ)Greater than125.535
Current Ratio (MRQ)Greater than114.525
Debt to Asset Ratio (MRQ)Less than10.084
Debt to Equity Ratio (MRQ)Less than10.092
Return on Equity (MRQ)Greater than0.15-0.076
Return on Assets (MRQ)Greater than0.05-0.069
Total5/10 (50.0%)

4.3. Technical Score

Let's check the technical score of Cardiff Oncology Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose1.550
Total1/1 (100.0%)



Latest Balance Sheet

Balance Sheet of 2022-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets123,631
Total Liabilities10,419
Total Stockholder Equity113,212
 As reported
Total Liabilities 10,419
Total Stockholder Equity+ 113,212
Total Assets = 123,631

Assets

Total Assets123,631
Total Current Assets119,755
Long-term Assets119,755
Total Current Assets
Cash And Cash Equivalents 18,717
Short-term Investments 95,586
Net Receivables 650
Other Current Assets 4,802
Total Current Assets  (as reported)119,755
Total Current Assets  (calculated)119,755
+/-0
Long-term Assets
Property Plant Equipment 3,692
Other Assets 184
Long-term Assets  (as reported)3,876
Long-term Assets  (calculated)3,876
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities8,245
Long-term Liabilities2,174
Total Stockholder Equity113,212
Total Current Liabilities
Short-term Debt 674
Accounts payable 1,425
Other Current Liabilities 6,146
Total Current Liabilities  (as reported)8,245
Total Current Liabilities  (calculated)8,245
+/-0
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt2,174
Long-term Liabilities  (as reported)2,174
Long-term Liabilities  (calculated)2,174
+/-0
Total Stockholder Equity
Common Stock4
Retained Earnings -289,835
Accumulated Other Comprehensive Income -779
Capital Surplus 403,822
Total Stockholder Equity (as reported)113,212
Total Stockholder Equity (calculated)113,212
+/-0
Other
Capital Stock4
Cash and Short Term Investments 114,303
Common Stock Shares Outstanding 43,333
Common Stock Total Equity4
Liabilities and Stockholders Equity 123,631
Net Debt -15,869
Net Invested Capital 113,212
Net Tangible Assets 113,212
Net Working Capital 111,510
Short Long Term Debt Total 2,848



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-31
> Total Assets 
0
0
0
0
0
360
490
1,039
1,182
9,952
8,571
11,665
11,665
9,625
29,151
27,156
24,459
36,193
32,762
28,897
45,832
43,644
77,023
71,446
66,009
56,723
53,004
43,950
33,925
12,561
12,218
12,285
10,409
21,768
17,921
14,172
14,533
13,868
11,922
13,087
11,815
30,129
39,450
134,727
129,573
143,734
141,312
149,544
139,204
131,261
123,631
123,631131,261139,204149,544141,312143,734129,573134,72739,45030,12911,81513,08711,92213,86814,53314,17217,92121,76810,40912,28512,21812,56133,92543,95053,00456,72366,00971,44677,02343,64445,83228,89732,76236,19324,45927,15629,1519,62511,66511,6658,5719,9521,1821,03949036000000
   > Total Current Assets 
0
0
0
0
0
140
290
842
706
9,440
8,001
11,048
11,048
8,524
27,998
26,069
23,263
35,030
31,574
27,720
44,473
41,902
74,818
68,381
60,892
51,620
47,978
38,950
29,729
8,655
8,552
9,469
7,840
19,643
16,044
12,765
12,336
11,820
9,977
11,354
10,283
28,819
38,189
133,356
128,570
142,871
137,769
146,127
135,806
127,414
119,755
119,755127,414135,806146,127137,769142,871128,570133,35638,18928,81910,28311,3549,97711,82012,33612,76516,04419,6437,8409,4698,5528,65529,72938,95047,97851,62060,89268,38174,81841,90244,47327,72031,57435,03023,26326,06927,9988,52411,04811,0488,0019,44070684229014000000
       Cash And Cash Equivalents 
0
0
0
0
0
20
160
700
587
9,304
7,815
10,820
10,820
8,302
27,799
25,837
22,871
34,674
31,164
27,294
43,996
41,294
74,150
67,493
59,989
22,579
22,569
13,915
10,183
7,784
7,434
8,226
6,657
18,486
15,066
11,453
11,330
10,791
9,032
10,195
9,277
27,755
36,405
130,981
14,662
10,581
13,165
11,943
20,052
20,965
18,717
18,71720,96520,05211,94313,16510,58114,662130,98136,40527,7559,27710,1959,03210,79111,33011,45315,06618,4866,6578,2267,4347,78410,18313,91522,56922,57959,98967,49374,15041,29443,99627,29431,16434,67422,87125,83727,7998,30210,82010,8207,8159,3045877001602000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
28,005
24,377
23,978
18,620
0
0
0
0
32
0
0
0
0
0
0
0
0
0
0
110,922
129,470
120,882
128,878
109,310
101,041
95,586
95,586101,041109,310128,878120,882129,470110,922000000000032000018,62023,97824,37728,0050000000000000000000000000
       Net Receivables 
0
0
0
0
0
0
90
99
77
106
128
168
168
57
70
79
129
60
62
57
59
100
67
99
62
159
85
100
80
157
178
77
114
124
129
168
116
122
152
203
106
109
204
320
242
308
395
535
447
551
650
65055144753539530824232020410910620315212211616812912411477178157801008515962996710059576260129797057168168128106779990000000
       Other Current Assets 
0
0
0
0
0
120
40
43
42
30
57
0
60
165
129
153
262
296
348
369
418
508
601
789
841
878
946
957
846
714
939
1,166
1,068
1,002
849
1,144
891
906
793
955
899
955
1,579
2,055
2,744
2,512
3,327
4,771
5,997
4,857
4,802
4,8024,8575,9974,7713,3272,5122,7442,0551,5799558999557939068911,1448491,0021,0681,166939714846957946878841789601508418369348296262153129165600573042434012000000
   > Long-term Assets 
0
0
0
0
0
220
200
197
476
512
570
617
617
1,102
1,152
1,087
1,196
1,164
1,188
1,177
1,359
1,742
2,205
3,065
5,117
5,103
5,026
5,000
4,196
3,906
3,666
2,816
2,569
2,125
1,877
1,407
2,197
2,048
1,946
1,733
1,532
1,310
1,262
1,371
1,003
863
3,543
3,417
3,398
3,847
3,876
3,8763,8473,3983,4173,5438631,0031,3711,2621,3101,5321,7331,9462,0482,1971,4071,8772,1252,5692,8163,6663,9064,1965,0005,0265,1035,1173,0652,2051,7421,3591,1771,1881,1641,1961,0871,1521,10261761757051247619720022000000
       Property Plant Equipment 
0
0
0
0
0
30
30
23
114
149
208
255
255
571
740
751
860
817
841
840
1,023
1,379
1,842
2,691
4,746
4,732
4,655
3,827
3,567
3,322
3,127
2,426
2,224
1,804
1,628
1,304
2,110
1,913
1,775
1,575
1,376
1,157
1,106
967
765
600
3,400
3,178
3,210
3,662
3,692
3,6923,6623,2103,1783,4006007659671,1061,1571,3761,5751,7751,9132,1101,3041,6281,8042,2242,4263,1273,3223,5673,8274,6554,7324,7462,6911,8421,3791,02384084181786075174057125525520814911423303000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
103
87
135
171
158
156
153
156
404
238
263
143
239
188
185
184
1841851882391432632384041561531561581711358710300000000000000000000000000000000000
> Total Liabilities 
0
0
0
0
0
5,560
4,130
5,271
5,516
4,462
3,596
9,496
9,496
12,096
8,012
6,764
6,706
18,864
20,409
20,547
22,270
25,525
22,164
22,744
24,850
24,150
26,229
24,182
23,245
9,050
8,273
5,779
5,729
4,291
3,941
4,088
4,847
5,020
5,266
5,775
5,672
5,745
5,928
6,570
4,756
4,816
7,768
9,127
9,102
10,787
10,419
10,41910,7879,1029,1277,7684,8164,7566,5705,9285,7455,6725,7755,2665,0204,8474,0883,9414,2915,7295,7798,2739,05023,24524,18226,22924,15024,85022,74422,16425,52522,27020,54720,40918,8646,7066,7648,01212,0969,4969,4963,5964,4625,5165,2714,1305,56000000
   > Total Current Liabilities 
0
0
0
0
0
3,420
1,150
1,430
1,533
1,236
758
730
730
1,462
1,361
2,009
2,032
1,979
3,122
4,488
5,305
4,950
6,969
8,201
10,122
10,889
6,565
7,797
8,958
7,462
5,082
3,946
3,854
3,218
2,667
2,965
3,285
3,694
4,171
4,782
4,881
4,962
5,442
6,119
4,479
4,579
5,042
6,559
6,664
8,481
8,245
8,2458,4816,6646,5595,0424,5794,4796,1195,4424,9624,8814,7824,1713,6943,2852,9652,6673,2183,8543,9465,0827,4628,9587,7976,56510,88910,1228,2016,9694,9505,3054,4883,1221,9792,0322,0091,3611,4627307307581,2361,5331,4301,1503,42000000
       Short-term Debt 
0
0
0
0
0
2,340
0
0
0
0
0
0
0
63
148
198
201
0
753
1,899
3,065
2,320
3,745
5,226
5,850
6,147
801
2,360
3,873
1,645
1,488
1,332
1,175
0
0
0
796
816
836
865
871
948
1,189
860
635
402
594
551
665
670
674
6746706655515944026358601,1899488718658368167960001,1751,3321,4881,6453,8732,3608016,1475,8505,2263,7452,3203,0651,89975302011981486300000002,34000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
71
305
0
0
0
0
0
0
0
0
000000003057100000000000000000000000000000000000000000
       Accounts payable 
0
0
0
0
0
730
750
928
947
531
140
0
176
298
159
287
427
380
462
748
485
1,111
1,100
1,041
1,297
1,115
925
1,131
968
603
675
825
652
565
476
665
467
526
492
656
599
1,156
610
1,366
803
543
396
1,439
1,261
1,522
1,425
1,4251,5221,2611,4393965438031,3666101,1565996564925264676654765656528256756039681,1319251,1151,2971,0411,1001,111485748462380427287159298176014053194792875073000000
       Other Current Liabilities 
0
0
0
0
0
350
400
502
586
705
618
0
555
1,101
1,054
1,524
1,404
1,600
1,908
1,842
1,756
1,519
2,124
1,934
2,974
3,627
4,839
4,307
4,116
5,215
2,918
1,789
2,027
2,653
2,190
2,300
2,022
2,352
2,842
3,260
3,412
2,858
3,643
3,893
3,041
3,634
4,052
4,569
4,738
6,289
6,146
6,1466,2894,7384,5694,0523,6343,0413,8933,6432,8583,4123,2602,8422,3522,0222,3002,1902,6532,0271,7892,9185,2154,1164,3074,8393,6272,9741,9342,1241,5191,7561,8421,9081,6001,4041,5241,0541,101555061870558650240035000000
   > Long-term Liabilities 
0
0
0
0
0
2,140
2,980
3,841
3,983
3,227
2,838
8,766
8,766
10,634
6,652
4,755
4,674
16,885
17,286
16,059
16,964
20,575
15,195
14,543
14,728
13,261
19,665
16,385
14,287
1,588
3,191
1,833
1,876
1,073
1,274
1,123
1,562
1,326
1,096
993
791
783
486
451
277
237
2,726
2,568
2,438
2,306
2,174
2,1742,3062,4382,5682,7262372774514867837919931,0961,3261,5621,1231,2741,0731,8761,8333,1911,58814,28716,38519,66513,26114,72814,54315,19520,57516,96416,05917,28616,8854,6744,7556,65210,6348,7668,7662,8383,2273,9833,8412,9802,14000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
323
275
14,703
13,979
13,053
12,012
12,882
11,519
11,246
10,373
9,031
0
14,176
12,700
0
0
0
0
0
0
0
0
0
0
0
0
234
0
0
0
0
0
0
0
0
0
00000000023400000000000012,70014,17609,03110,37311,24611,51912,88212,01213,05313,97914,703275323000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
18
5
132
141
119
279
441
269
231
35
0
0
0
0
0000352312694412791191411325180000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,432
4,399
2,182
3,211
3,006
4,953
7,693
3,676
3,297
2,763
2,710
0
2,209
1,587
1,588
3,191
1,833
1,876
1,073
1,274
1,123
42
18
5
4
2
46
190
285
78
17
5
0
0
0
0
0000517782851904624518421,1231,2741,0731,8761,8333,1911,5881,5872,20902,7102,7633,2973,6767,6934,9533,0063,2112,1824,3994,432000000000000000
> Total Stockholder Equity
0
0
0
0
0
-5,210
-3,640
-4,231
-4,334
5,489
4,975
0
2,169
-2,471
21,138
20,392
17,753
17,329
12,354
8,350
23,563
18,119
54,858
48,701
41,159
32,573
26,774
19,768
10,680
3,511
3,945
6,506
4,679
17,477
13,980
10,084
9,686
8,848
6,656
7,311
6,143
24,384
33,523
128,158
124,817
138,918
133,544
140,417
130,102
120,474
113,212
113,212120,474130,102140,417133,544138,918124,817128,15833,52324,3846,1437,3116,6568,8489,68610,08413,98017,4774,6796,5063,9453,51110,68019,76826,77432,57341,15948,70154,85818,11923,5638,35012,35417,32917,75320,39221,138-2,4712,16904,9755,489-4,334-4,231-3,640-5,21000000
   Common Stock
0
0
0
0
0
10
10
6
7
1
1
0
2
2
2
2
2
2
2
2
2
2
3
3
3
3
3
3
3
3
4
5
6
7
8
8
8
8
8
8
9
10
10
4
4
4
4
4
4
4
4
4444444410109888888765433333333222222222201176101000000
   Retained Earnings Total Equity-289,835-281,2580-259,810-250,362-243,443-236,680-231,495-224,892-220,390-212,993-208,898-204,649-200,502-196,370-192,191-188,027-184,251-177,729-173,046-170,471-166,173-158,121-148,1150-129,364-119,156-108,887-101,500-98,758-88,572-81,392-76,702-71,321-70,242-67,043000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
0
0
-222
0
0
0
-260
-260
0
0
-349
0
0
0
-534
-560
-644
-733
-855
-1
3
-5
-11
-14
-14
-15
-2,071
-2,279
-2,176
-2,352
-2,110
-1,266
-1,308
-1,351
-2,604
-2,724
-2,838
-2,953
0
-67
-10
16
-142
-748
-982
-779
-779-982-748-14216-10-670-2,953-2,838-2,724-2,604-1,351-1,308-1,266-2,110-2,352-2,176-2,279-2,071-15-14-14-11-53-1-855-733-644-560-534000-34900-260-260000-2220000000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
87,433
87,993
88,649
89,054
89,740
112,133
116,875
156,356
157,585
160,313
161,931
0
167,891
168,812
169,694
174,427
179,547
182,402
201,721
201,999
202,268
207,653
210,706
212,463
217,173
219,806
247,528
260,807
361,820
363,350
383,611
384,551
400,503
0
402,710
403,822
403,822402,7100400,503384,551383,611363,350361,820260,807247,528219,806217,173212,463210,706207,653202,268201,999201,721182,402179,547174,427169,694168,812167,8910161,931160,313157,585156,356116,875112,13389,74089,05488,64987,99387,433000000000000000
   Treasury Stock000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
37,120
38,690
39,582
40,430
53,694
53,840
0
57,630
59,126
87,141
87,782
87,993
88,649
89,054
90,273
112,692
117,519
157,089
158,440
160,313
161,931
166,338
167,891
168,812
169,694
174,427
181,618
184,681
203,897
204,351
204,378
207,315
210,650
212,648
218,805
221,851
247,601
261,357
359,649
361,559
382,366
383,885
400,364
401,655
402,710
403,047
403,047402,710401,655400,364383,885382,366361,559359,649261,357247,601221,851218,805212,648210,650207,315204,378204,351203,897184,681181,618174,427169,694168,812167,891166,338161,931160,313158,440157,089117,519112,69290,27389,05488,64987,99387,78287,14159,12657,630053,84053,69440,43039,58238,69037,12000000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.